Provision of clinical research samples in the UK: We work closely with you to provide market insights needed in order to implement the best strategy to meet your commercial drug supply requirements. Our client testimonials attest to our unique, collaborative approach, which adds longstanding value and strong partnerships. Our aim is to understand your goals and to work to minimize waste, allowing you to reinvest those savings back into your R&D initiatives. We hold ourselves to the highest standards, delivering on time, and most importantly, with uncompromised quality and integrity. See more information on pharmaceutical risk mitigation and competitiveness.
We profoundly understand and recognize the numerous risks associated with global drug procurement. We also appreciate the many complexities associated with worldwide storage and distribution of clinical trial supplies. Our team knows the importance of an efficient, robust supply chain — audited & approved — that promotes excellence, security and accountability. We provide batch traceability, supporting documentation (i.e. Certificates of Analysis (CofAs), Batch Release Certificates (BRCs), GMP Statements, stability data, Fit-for-Use (FFU) Statements, Certificates of Conformance (CofCs), Certificates of Origin (CofOs), etc.) and temperature monitoring data – delivering product pedigree and authenticity.
From sample requests to global bulk supply procurement and distribution, we work as an extension of your team to guide you through the appropriate steps to mitigate risks. From start-to-finish, we utilize our extensive expertise and breadth of knowledge to navigate: Market Intelligence; Supply Chain Planning; Risk Management; Sourcing; Waste Management; Storage & Distribution; Documentation Management; Returns, Reconciliation & Destruction Services.
Our temperature-controlled capabilities include 2°- 8°C and 15°- 25°C facilities, as well as access to specialist transport to manage deliveries around the world according to product temperature requirements. Extensive capabilities: Our capabilities include stock receipt, import & export expertise, in-territory regulatory specialists, product reconciliation and destruction services. You can trust us: Our highly trained logistics team is dedicated to providing a robust clinical trial supply chain and trusted product integrity with regulatory compliant distribution through validated temperature-controlled logistics. We provide the peace-of-mind you need, offering you with dedicated clinical trial supply chain solutions to meet the explicit needs of your clinical programs. Discover more details on https://www.clientpharma.com/.
Under this partnership, clients will now enjoy an expanded reach by leveraging ClientPharma’s global sourcing, procurement and distribution logistics while also having the ability to utilize the RxStudy CardTM, TrialCard’s virtual inventory supply solution that has been augmented to place physical inventories of medication at sites for protocol designs that require immediate dosing. This will cut supply costs by 50% and reduce clinical supply teams’ efforts by 80%. TrialCard Incorporated is a full-service life sciences commercialization partner that provides comprehensive solutions that span the entire biopharmaceutical value chain. In addition to a foundation of fully integrated, digitally enabled patient support services, its broader offerings include everything from late-stage clinical trial management to post-marketing HCP engagement services and proprietary data-as-a-service payer intelligence and insights. Founded in 2000, TrialCard provides commercialization needs for more than 160 life science customers and has connected over 35 million patients with more than $18 billion in branded drug savings to date. The company is headquartered in Morrisville, North Carolina.
Supply and demand of pharmaceuticals are mutually exclusive. The supply chain is wholly reliant upon pharmaceutical companies being able to effectively forecast demand for a particular product. The process of forecasting is often made difficult when a new medicine has just been brought to market or rapid deployment of a drug needs to happen in response to a pandemic due to a lack of concrete evidence to base estimations on. In a survey of pharmaceutical Senior Managers it was reported that the majority of pharmaceutical companies had miscalculated demand for new medicines by up to 25%. Michael Lehmann, executive vice president of sales and marketing for Patheon, a global provider of outsourced pharmaceutical development and manufacturing said, “Making accurate demand forecasts is extremely challenging for pharmaceutical companies”.